These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26137573)

  • 21. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens.
    Alqahtani QM; Crowley A; Rapp S; Cushman-Vokoun AM
    Lab Med; 2016 Feb; 47(1):30-8. PubMed ID: 26732779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    Weyn C; Van Raemdonck S; Dendooven R; Maes V; Zwaenepoel K; Lambin S; Pauwels P
    BMC Cancer; 2017 Feb; 17(1):139. PubMed ID: 28201998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
    Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
    Awidi M; Ababneh N; Shomaf M; Al Fararjeh F; Owaidi L; AlKhatib M; Al Tarawneh B; Awidi A
    PLoS One; 2019; 14(12):e0226473. PubMed ID: 31881025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients.
    Brotto K; Malisic E; Cavic M; Krivokuca A; Jankovic R
    Dig Dis Sci; 2013 Apr; 58(4):998-1003. PubMed ID: 23108567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer.
    Wang J; Yang H; Shen Y; Wang S; Lin D; Ma L; Han X; Shi Y
    Cancer Biomark; 2013; 13(2):89-97. PubMed ID: 23838137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
    Zekri J; Baghdadi MA; Alardati H; Khallaf H; Kabanja JH
    Exp Mol Pathol; 2019 Oct; 110():104270. PubMed ID: 31207216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing.
    Zhang H; Zheng X; Ji T; Fu L; Bai D; Liao Y; Zhang H; Ding Y; Zheng L
    Cell Biochem Biophys; 2012 Apr; 62(3):415-20. PubMed ID: 22048888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
    Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
    Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
    Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [KRAS Genetic Mutation Analysis Using the Clinical FFPE Samples of Colorectal Carcinomas: Comparative Study among 5 Methods].
    Okada K; Asano N; Kajiura Y; Shimoyama Y; Matsumoto H; Matsushita T
    Rinsho Byori; 2015 Oct; 63(10):1144-51. PubMed ID: 26897849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.
    Angulo B; García-García E; Martínez R; Suárez-Gauthier A; Conde E; Hidalgo M; López-Ríos F
    J Mol Diagn; 2010 May; 12(3):292-9. PubMed ID: 20203003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
    Veldore VH; Rao MR; Prabhudesai SA; Tejaswi R; Kakara S; Pattanayak S; Krishnamoorthy N; Tejaswini BN; Hazarika D; Gangoli A; Rahman SM; Dixit J; Naik R; Diwakar RB; Satheesh CT; Shashidhara HP; Patil S; Gopinath KS; Kumar BS
    Indian J Cancer; 2014; 51(4):531-7. PubMed ID: 26842186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.